Samsung Biologics Co Ltd (207940):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Samsung Biologics Co Ltd (207940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8221
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development, contract manufacturing, aseptic fill and finish and project management. Samsung Biologics cell culture development process includes upstream, downstream and analytical technology. Samsung Biologics’ provides manufacturing and quality assurance for the clinical and commercial products. The company also provides infrastructure for partnership with other organizations to develop, refine, and distribute the bio-pharmaceutical products. It owns manufacturing facilities for cell culture development, purification, quality control, MSAT laboratory. Samsung Biologics is headquartered in Incheon, South Korea.

Samsung Biologics Co Ltd (207940) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
MilliporeSigma to Enter into Agreement with Samsung Biologics 10
AstraZeneca Forms Joint Venture with Samsung Biologics 11
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 12
Equity Offering 13
Samsung Biologics Raises USD2.03 Billion in IPO 13
Acquisition 14
Biogen to Acquire 44.5% Stake in Samsung Bioepis from Samsung BioLogics for USD700 Million 14
Samsung Biologics Co Ltd – Key Competitors 15
Samsung Biologics Co Ltd – Key Employees 16
Samsung Biologics Co Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Financial Announcements 18
Jul 23, 2018: Samsung BioLogics announces sales of KRW 125.4 billion and profits of KRW 23.7 billion in 2Q 2018 18
Jan 31, 2018: Samsung BioLogics Sales and Profits in 2017 19
Apr 25, 2017: Samsung BioLogics announces its financial results for 1Q 2017 20
Jan 24, 2017: Samsung BioLogics sales and profits in 2016 21
Legal and Regulatory 22
Oct 22, 2018: Samsung BioLogics obtains an Authorized Economic Operator (AEO) certificate 22
Jul 12, 2018: Samsung BioLogics violated accounting standards 23
Jun 21, 2018: Samsung BioLogics Receives Health Canada Approval 24
May 24, 2018: Samsung BioLogics Receives an additional FDA Approval for its world largest Plant’s Production 25
Apr 25, 2018: Samsung BioLogics becomes the first in the South Korean pharma industry to achieve ISO 22301 Certificate 26
Apr 13, 2018: Samsung BioLogics receives the 1st EMA Approval for its Plant No. 2 production 27
Government and Public Interest 28
Oct 17, 2018: Samsung BioLogics may face disciplinary action for alleged accounting breach 28
Other Significant Developments 29
Oct 01, 2018: Samsung BioLogics plant 3 starts production 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Samsung Biologics Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MilliporeSigma to Enter into Agreement with Samsung Biologics 10
AstraZeneca Forms Joint Venture with Samsung Biologics 11
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 12
Samsung Biologics Raises USD2.03 Billion in IPO 13
Biogen to Acquire 44.5% Stake in Samsung Bioepis from Samsung BioLogics for USD700 Million 14
Samsung Biologics Co Ltd, Key Competitors 15
Samsung Biologics Co Ltd, Key Employees 16
Samsung Biologics Co Ltd, Joint Venture 17

List of Figures
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Samsung Biologics Co Ltd (207940):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ClearStream Energy Services Inc:企業の戦略・SWOT・財務情報
    ClearStream Energy Services Inc - Strategy, SWOT and Corporate Finance Report Summary ClearStream Energy Services Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • PT. Millennium Pharmacon International TBK (SDPC):企業の財務・戦略的SWOT分析
    PT. Millennium Pharmacon International TBK (SDPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • B2W – Companhia Global Do Varejo:企業の戦略・SWOT・財務分析
    B2W - Companhia Global Do Varejo - Strategy, SWOT and Corporate Finance Report Summary B2W - Companhia Global Do Varejo - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Matrix Composites & Engineering Ltd (MCE):企業の財務・戦略的SWOT分析
    Summary Matrix Composites & Engineering Ltd (Matrix) is a manufacturer and supplier of engineered products and services. The company manufactures and distributes engineered products for developing and utilizing advanced composite and polymer materials technologies. Its products include well construc …
  • Kuzbasskaya Toplivnaya Company:企業の戦略・SWOT・財務分析
    Kuzbasskaya Toplivnaya Company - Strategy, SWOT and Corporate Finance Report Summary Kuzbasskaya Toplivnaya Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Centrica Plc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Centrica Plc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Centrica Plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF …
  • Gilead Sciences Inc (GILD)-製薬・医療分野:企業M&A・提携分析
    Summary Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) in …
  • First Abu Dhabi Bank (FAB):企業の財務・戦略的SWOT分析
    First Abu Dhabi Bank (FAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Wirecard AG:企業のM&A・事業提携・投資動向
    Wirecard AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wirecard AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Cardiac Science Corp:企業の戦略的SWOT分析
    Cardiac Science Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Hanwha Life Insurance Co Ltd:戦略・SWOT・企業財務分析
    Hanwha Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Hanwha Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Anika Therapeutics Inc (ANIK):企業の財務・戦略的SWOT分析
    Anika Therapeutics Inc (ANIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Highland Gold Mining Limited:企業の戦略・SWOT・財務分析
    Highland Gold Mining Limited - Strategy, SWOT and Corporate Finance Report Summary Highland Gold Mining Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Tokyo Gas Co Ltd (9531)-エネルギー分野:企業M&A・提携分析
    Summary Tokyo Gas Co Ltd (Tokyo Gas) is a gas utility that produces, supplies and markets liquefied natural gas (LNG). It also produces, supplies and sells electricity. Tokyo Gas also has overseas upstream, midstream and downstream businesses. It provides engineering solutions, gas appliances and ga …
  • Kineta Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Kineta Inc (Kineta) is a biotech company that develops novel immuno-therapies. The company offers small-molecule compounds that target RIG-I-like receptor pathways and intracellular IRF3-inducing pathways for applications in cancer. Its KCP-400 is a novel non-opioid therapy for the treatment …
  • SK Kaken Co Ltd (4628):企業の財務・戦略的SWOT分析
    SK Kaken Co Ltd (4628) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Shutterfly Inc:企業の戦略的SWOT分析
    Shutterfly Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Corby Spirit and Wine Limited:企業の戦略・SWOT・財務情報
    Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report Summary Corby Spirit and Wine Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Australian Postal Corporation:企業の戦略・SWOT・財務情報
    Australian Postal Corporation - Strategy, SWOT and Corporate Finance Report Summary Australian Postal Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Crescent Point Energy Corp (CPG):石油・ガス:M&Aディール及び事業提携情報
    Summary Crescent Point Energy Corp (Crescent Point) is an oil and gas company. It acquires, explores, develops and produces light and medium crude oil, heavy crude oil, tight oil, natural gas liquids, shale gas and conventional natural gas. The company holds interest in light and medium oil and natu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆